Shares of Novavax, Inc. (NASDAQ:NVAX) ended Tuesday session in green amid volatile trading. The shares closed up +0.06 points or 3.92% at $1.59 with 7.35 million shares getting traded. Post opening the session at $1.50, the shares hit an intraday low of $1.50 and an intraday high of $1.63 and the price vacillated in this range throughout the day. The company has a market cap of $422.90 million and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) announced topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults. The Resolve™ trial, a Phase 3 trial of our RSV F Vaccine in 11,856 older adults (60 years of age and older), did not meet the pre-specified primary or the secondary efficacy objectives, and did not demonstrate vaccine efficacy. Consistent with our previous clinical experience, the vaccine was well tolerated.
Phase 3 Resolve™ Trial
The trial was a randomized, observer-blinded, placebo-controlled trial conducted at 60 sites in the United States. The primary objective of the Resolve trial was to demonstrate efficacy in the prevention of moderate-severe RSV-associated lower respiratory tract disease (RSV msLRTD), as defined by the presence of multiple lower respiratory tract symptoms. The secondary objective of the trial was to demonstrate efficacy of the RSV F Vaccine in reducing the incidence of all symptomatic respiratory disease due to RSV (RSV ARD). Finally, the trial also evaluated the safety of the unadjuvanted, 135 microgram dose of the RSV F Vaccine compared to placebo.
Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Tuesday session in green amid volatile trading. The shares closed up +0.16 points or 1.39% at $11.67 with 3.25 million shares getting traded. Post opening the session at $11.74, the shares hit an intraday low of $11.57 and an intraday high of $11.95 and the price vacillated in this range throughout the day. The company has a market cap of $2.73 billion and the numbers of outstanding shares have been calculated to be 230.33 million shares.
Exelixis, Inc. (EXEL) announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company’s Board of Directors. Ms. Smith’s appointment.
Ms. Smith has nearly two decades of operational leadership experience in high growth public, private, startup, and established biopharmaceutical businesses. She currently serves as president and chief executive officer of Raptor Pharmaceuticals, a commercial-stage, global innovator in the development and commercialization of orphan disease therapies. Ms. Smith previously held key commercial and strategic leadership positions at companies including Enobia Pharma, Jazz Pharmaceuticals, and Genzyme.
“I’m delighted to welcome Julie Anne Smith to the Exelixis board of directors,” said Stelios Papadopoulos, Ph.D., an Exelixis-co-founder and chairman of the company’s board. “Her deep commercial expertise will serve Exelixis well as the company continues to execute on the launch of its latest therapy, CABOMETYX, following regulatory approval in the United States earlier this year.”